About David Sans
Form D filings for Calidi Biotherapeutics in 2023 list David Sans as chief of corporate development.
David Sans reports to the SEC as an officer of 1 public company.
David Sans first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name David Sans in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people David Sans works with at each company, as listed on that company's latest Form D.
Calidi Biotherapeutics, Inc. · Form D, Jun 29, 2023
AC
Allan Camaisa
CEO and director
HL
Heehyoung Lee
Director
JS
James Schoeneck
Director
AZ
Alfonso Zulueta
Director
AS
Anthony Santidrian
Executive officer
BM
Boris Minev
Interim Chief Medical Officer
ST
Stephen Thesing
Chief Business Officer
TK
Tony Kalajian
Interim Chief Financial Officer
AP
Amish Patel
Vice President of Technical Operations
WP
Wendy Pizarro
Executive officer
SL
Scott Leftwich
Director
GN
George Ng
Director